* Newstin.com is for sale! * After achieving our strategic milestone, we are offering for sale: Newstin.com and all 14 related domains featuring 1 million unique visitors per month + continuously updated news database of 37 million articles in 12 world languages from 166,000 global and weighted sources + 2.1 billion metadata * To seize this unique chance, contact invest@newstin.com. * Newstin.com is for sale! *

Callisto Pharmaceuticals

Pawfect Foods acquires Synergy Pharmaceuticals

pharmaceutical-business-review.com
Jul 23, 2008 8 related
        

Pawfect Foods has acquired Synergy Pharmaceuticals in exchange for shares of its common stock issued to Callisto Pharmaceuticals. The company has also completed a $3 million private placement. The company has cancelled 1.98...

add comment

Callisto initiates Phase I irritable bowel syndrome trial

pharmaceutical-business-review.com
Jun 7, 2008 2 related
        

Callisto Pharmaceuticals has announced that through its wholly-owned subsidiary, Synergy Pharmaceuticals, it has initiated oral dosing of healthy volunteers in a Phase I clinical trial of SP-304. The primary objective of the...

add comment
                   

InPlay: Protez Pharmaceuticals confirms it will be acquired by Novartis (Briefing.com)

yahoo.com
Jun 4, 2008 3 related
        

7:56AM Eldorado Gold says that its offer to Frontier shareholders continues to be "full and fair" 8.28 : Co announces that it completed its in-depth review of the Directors' Circular issued by Frontier Pacific Mining on May 26,...

add comment
                   

Callisto Pharmaceuticals Reports Promising Interim Phase II Data For Atiprimod In Advanced...

medicalnewstoday.com
May 20, 2008
        

Callisto Pharmaceuticals, Inc. (AMEX: KAL; FWB: CA4), a developer of new drug treatments in the fight against cancer and gastrointestinal disorders, announced today promising interim data from the company's ongoing open-label Phase II clinical trial of Atiprimod to treat low to intermediate grade...

add comment
                   

Callisto Pharmaceuticals Reports Promising Interim Phase II Data for Atiprimod in Advanced...

yahoo.com
May 16, 2008 1 related
        

NEW YORK----Callisto Pharmaceuticals, Inc. , a developer of new drug treatments in the fight against cancer and gastrointestinal disorders, announced today promising interim data from the company's ongoing open-label Phase II clinical trial of Atiprimod to treat low to intermediate grade...

add comment
                   

Callisto Pharmaceuticals' Interim Phase II Data Of Atiprimod In Advanced Carcinoid Cancer To Be...

medicalnewstoday.com
Apr 16, 2008
        

Callisto Pharmaceuticals, Inc. ... (AMEX: KAL; FWB: CA4), a developer of new drug treatments in the fight against cancer and gastrointestinal disorders, announced that interim data from the company's ongoing open-label Phase II clinical trial of Atiprimod in advanced...

add comment
                   
pharmiweb.co.uk: Genetic Engineering News - Current Issue pharmiweb.co.uk

Callisto Pharmaceuticals' Interim Phase II Data of Atiprimod in Advanced Carcinoid Cancer to be...

yahoo.com
Apr 14, 2008 5 related
        

NEW YORK----Callisto Pharmaceuticals, Inc. , a developer of new drug treatments in the fight against cancer and gastrointestinal disorders, announced today that interim data from the company's ongoing open-label Phase II clinical trial of Atiprimod in advanced carcinoid cancer, will be presented...

add comment
pharmiweb.co.uk: Genetic Engineering News - Current Issue pharmiweb.co.uk

Callisto Pharmaceuticals Files IND For SP-304 (Guanilib) In Chronic Constipation And Irritable...

medicalnewstoday.com
Apr 10, 2008 4 related
        

Callisto Pharmaceuticals, Inc. (AMEX: KAL; FWB: CA4) announced that through its wholly-owned subsidiary, Synergy Pharmaceuticals, Inc. it filed an IND on April 2, 2008 with the FDA for SP-304 (also called Guanilib) for the treatment of chronic constipation and constipation-predominant irritable...

add comment

Callisto Announces Guanilib Presentation at the 5th Annual Meeting of Cancer Drugs Research and...

yahoo.com
Feb 19, 2008 1 related
        

NEW YORK----Callisto Pharmaceuticals, Inc. , a developer of new drug treatments in the fight against cancer and gastrointestinal disorders, announced today that Dr. Kunwar Shailubhai, Sr. ... Tuesday February 19, 9:17 am ET NEW YORK--(BUSINESS WIRE)--Callisto...

add comment